biopharminternational.com
EC Approves Tepkinly as First Bispecific-Based Therapy for Follicular Lymphomahttps://www.biopharminternational.com/view/european-commission-approves-tepkinly-plus-r2-as-first-bispecific-based-therapy-for-relapsed-or-refractory-follicular-lymphomaJul 8, 2026 4:41 PM